Last year marked an increase in federal securities class action filings, with plaintiffs filing 212 cases in 2023, up from 197 in 2022 and ending an overall decline in filings since 2019. Life sciences companies remained popular targets, accounting for approximately one in five of these filings.1 In this white paper, we examine 2023’s filing and decision trends, providing insights for life sciences companies to prudently navigate the litigation landscape.